Thoracoscopic Lobectomy

A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer

Rebecca P. Petersen, Mimi Ceppa, Eric M. Toloza, William R. Burfeind, David H. Harpole, Steven I. Hanish, Thomas A. D'Amico

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background: Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy. Methods: The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and χ2 or R×C contingency tables were used to compare continuous and categoric variables, respectively. Results: Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76%) received induction radiotherapy as well: 66 of 85 (78%) in the thoracotomy group and 8 of 12 (67%) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p <0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure. Conclusions: Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy.

Original languageEnglish (US)
Pages (from-to)214-219
Number of pages6
JournalAnnals of Thoracic Surgery
Volume82
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Chest Tubes
Thoracotomy
Therapeutics
Respiratory Insufficiency
Length of Stay
Pneumonia
Hemorrhage
Thoracoscopy
Induction Chemotherapy
Survival
Mortality
Hospitalization
Radiotherapy
Retrospective Studies
Students

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Thoracoscopic Lobectomy : A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer. / Petersen, Rebecca P.; Ceppa, Mimi; Toloza, Eric M.; Burfeind, William R.; Harpole, David H.; Hanish, Steven I.; D'Amico, Thomas A.

In: Annals of Thoracic Surgery, Vol. 82, No. 1, 07.2006, p. 214-219.

Research output: Contribution to journalArticle

Petersen, Rebecca P. ; Ceppa, Mimi ; Toloza, Eric M. ; Burfeind, William R. ; Harpole, David H. ; Hanish, Steven I. ; D'Amico, Thomas A. / Thoracoscopic Lobectomy : A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer. In: Annals of Thoracic Surgery. 2006 ; Vol. 82, No. 1. pp. 214-219.
@article{6d6c43bac2c946a8a68c8cd6d9be2334,
title = "Thoracoscopic Lobectomy: A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer",
abstract = "Background: Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy. Methods: The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and χ2 or R×C contingency tables were used to compare continuous and categoric variables, respectively. Results: Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76{\%}) received induction radiotherapy as well: 66 of 85 (78{\%}) in the thoracotomy group and 8 of 12 (67{\%}) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p <0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure. Conclusions: Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy.",
author = "Petersen, {Rebecca P.} and Mimi Ceppa and Toloza, {Eric M.} and Burfeind, {William R.} and Harpole, {David H.} and Hanish, {Steven I.} and D'Amico, {Thomas A.}",
year = "2006",
month = "7",
doi = "10.1016/j.athoracsur.2006.02.051",
language = "English (US)",
volume = "82",
pages = "214--219",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Thoracoscopic Lobectomy

T2 - A Safe and Effective Strategy for Patients Receiving Induction Therapy for Non-Small Cell Lung Cancer

AU - Petersen, Rebecca P.

AU - Ceppa, Mimi

AU - Toloza, Eric M.

AU - Burfeind, William R.

AU - Harpole, David H.

AU - Hanish, Steven I.

AU - D'Amico, Thomas A.

PY - 2006/7

Y1 - 2006/7

N2 - Background: Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy. Methods: The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and χ2 or R×C contingency tables were used to compare continuous and categoric variables, respectively. Results: Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76%) received induction radiotherapy as well: 66 of 85 (78%) in the thoracotomy group and 8 of 12 (67%) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p <0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure. Conclusions: Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy.

AB - Background: Thoracoscopic lobectomy is an accepted oncologic approach for early stage non-small cell lung cancer (NSCLC). We conducted a retrospective study of patients who underwent lobectomy after induction therapy to determine the feasibility of thoracoscopic lobectomy compared with conventional thoracotomy lobectomy. Methods: The outcomes of 97 consecutive patients with NSCLC who received induction therapy followed by lobectomy from 1996 to 2005 were reviewed. Outcome variables analyzed included complete resection, chest tube duration, length of hospitalization, 30-day mortality, hemorrhage, pneumonia, respiratory failure, and other major complications. The Student t test and χ2 or R×C contingency tables were used to compare continuous and categoric variables, respectively. Results: Lobectomy was performed by thoracotomy in 85 patients and thoracoscopically in 12 patients (1 conversion), with complete resection in all patients. All patients received induction chemotherapy, and 74 (76%) received induction radiotherapy as well: 66 of 85 (78%) in the thoracotomy group and 8 of 12 (67%) in the thoracoscopy group. The overall median survival was 2.3 years, with no difference between the groups. Patients undergoing a thoracoscopic lobectomy had a shorter median hospital stay (3.5 vs 5 days, p = 0.0024) and chest tube duration (2 vs 4 days, p <0.001). There were no significant differences in 30-day mortality, hemorrhage, pneumonia, or respiratory failure. Conclusions: Thoracoscopic lobectomy is a feasible approach for selected patients undergoing resection after induction therapy, and is associated with shorter hospital stay and chest tube duration. Long-term follow-up of survival will determine the role of thoracoscopic lobectomy in the management of patients after induction therapy.

UR - http://www.scopus.com/inward/record.url?scp=33745212861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745212861&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2006.02.051

DO - 10.1016/j.athoracsur.2006.02.051

M3 - Article

VL - 82

SP - 214

EP - 219

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -